Spotlight On... FDA writes up another 'inadequate' Lupin plant in India; FDA prioritizes generic apps for meds with no competition; Abbott, Glenmark win temporary reprieves from Indian drug ban; and more...

It seems to be two steps forward, one step back for India's Lupin in its efforts to build its business in the U.S. A week after the drugmaker closed a deal that gets it its first U.S. manufacturing facility, another of its plants in India has been found lacking by the FDA. More from FiercePharmaManufacturing

@FiercePharma: ICYMI yesterday: Patent challenger Bass wins another review bid, this time on Acorda's Ampyra. Story | Follow @FiercePharma

@CarlyHFierce: Ex-Sanofi, Schering CEOs were on a short list to replace Valeant chief Pearson: WSJ. More | Follow @CarlyHFierce

> The FDA moved to prioritize reviews of generics of drugs made by only one company, which could circumvent large price increases like those brought to light by former Turing Pharmaceuticals CEO Martin Shkreli. Report

> An Indian court gave Abbott's India unit and two domestic drugmakers, Glenmark Pharmaceuticals and Macleods, a temporary reprieve from a ban on several combination meds. Report

> Roche ($RHHBY) inked a deal to integrate its blood glucose monitors with Cellnovo Group's diabetes management system. Report

Medical Device News

@FierceMedDev: Anne Wojcicki, Elizabeth Holmes, Andrew Conrad make 2016's most influential people in biopharma list. FierceBiotech feature | Follow @FierceMedDev

@VarunSaxena2: FDA panel set to review its first bioresorbable stent, Abbott's Absorb. Report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Hospitals join drug price-fighting battalion with plans to crack down on spending. Report | Follow @EmilyWFierce

> NIH-funded researcher making progress on nature-inspired 'smart' contact lens. Story

> GE Healthcare JV rolls out digital pathology software for cancer diagnosis. More

> Philips readies for mid- to high-single-digit HealthTech growth with reorg, lighting disposal. Article

Biotech News

@FierceBiotech: Tiny Celator surges on promising cancer data and preps an FDA submission. Article | Follow @FierceBiotech

@JohnCFierce: Gee, Lilly drops function as a co-primary endpoint for sola. Anyone a wee bit nervous? Release | Follow @JohnCFierce

> Lilly moves the goal line in its make-or-break Alzheimer's trial. Report

> Roche's new PD-L1 bladder cancer drug could be on the market by September. More

> Roche bets up to $1B on Blueprint's precision medicine platform. Article

Drug Delivery News

> 'Smart' diabetes patch uses real beta cells to react to blood sugar and release insulin. Story

> Artificial liposomes bypass immune system to release cardio drugs. More

> Harvard team develops blood-brain-barrier-on-a-chip to study drug delivery. Report

> EyeGate adds drug-delivering hydrogel to its pipeline with acquisition of Jade Therapeutics. Story

> Eli Lilly reports promising early-stage results for its fast-acting insulin formulation. Article

Pharma Manufacturing News

> Lupin plant in Goa smacked by the FDA. Report

> China's FDA urged to get track and trace system in place. Item

> Iran drugmaker agrees to build plant in Azerbaijan. Report

> Pfizer, Abbott cough syrups banned by Indian regulator in fight over opiates. Article

> Amgen strikes deal with Patheon for 'flexible manufacturing capacity.' Story

Pharma Asia News

> India still reviewing prospects for mandated cuts in drug prices. Item

> GSK's Witty hears the rhythm in China's drumbeat for lower prices. More

> India lifts alert on Roche's Avastin use for eye injection. Story

> SK Bio's epilepsy drug gets U.S. FDA exemption from PhIII efficacy step. News

> India's Dr. Reddy's works with Turkey's TR-Pharm on biosimilars. Article

And Finally... The FDA is investigating a video that shows a man urinating on one of Kellogg Co's assembly lines. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.